Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir

John W. Holladay, Michael J. Dewey, Bozena B. Michniak, Hugh Wiltshire, Daniel L. Halberg, Paul Weigl, Zhenmin Liang, Kathryn Halifax, W. Edward Lindup and David J. Back
Drug Metabolism and Disposition March 2001, 29 (3) 299-303;
John W. Holladay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Dewey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bozena B. Michniak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh Wiltshire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel L. Halberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Weigl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenmin Liang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Halifax
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Edward Lindup
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Back
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The purpose of this study was to characterize the relationship between plasma protein binding and the pharmacokinetic disposition of saquinavir during a normal and elevated alpha-1-acid glycoprotein condition. The extent of plasma binding of [14C]saquinavir to human plasma, human albumin, and human alpha-1-acid glycoprotein was also assessed. Transgenic mice, which overexpress plasma alpha-1-acid glycoprotein, and control mice were given a single intravenous injection of saquinavir (10 mg/kg) and plasma samples were harvested as a function of time. The extent of [14C]saquinavir (0.5–30 μg/ml) plasma protein binding in each group of mice was determined by ultrafiltration. Plasma saquinavir concentrations from in vivo administration were determined by high performance liquid chromatography with tandem mass spectrometry. Saquinavir binding in human plasma and control mouse plasma was similar (approximately 3% unbound). In contrast, the extent of binding was significantly increased in transgenic mice (1.5% unbound). Furthermore, saquinavir was more extensively bound to alpha-1-acid glycoprotein than to albumin (2.1 versus 11.5% unbound). The systemic clearance and volume of distribution of saquinavir were significantly reduced in transgenic mice compared with control mice. The results of this study show that alpha-1-acid glycoprotein is the predominant plasma protein to which saquinavir binds. In addition, elevations in plasma alpha-1-acid glycoprotein considerably alter the pharmacokinetic disposition of saquinavir. This is consistent with the observations that systemic exposure to saquinavir in human immunodeficiency virus patients is greater than that in healthy volunteers and that alpha-1-acid glycoprotein levels increase with the degree of HIV infection.

Footnotes

  • Send reprint requests to: John W. Holladay, Ph.D., Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 522, Little Rock, AR 72205-7199. E-mail: holladayjohnw{at}exchange.uams.edu

  • Abbreviations used are::
    HIV
    human immunodeficiency virus, AGP, alpha-1-acid glycoprotein
    HPLC
    high performance liquid chromatography
    ICG
    indocyanine green
    AUC
    area under the saquinavir plasma concentration versus time profile
    fu
    unbound fraction
    • Received March 23, 2000.
    • Accepted October 11, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (3)
Drug Metabolism and Disposition
Vol. 29, Issue 3
1 Mar 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir

John W. Holladay, Michael J. Dewey, Bozena B. Michniak, Hugh Wiltshire, Daniel L. Halberg, Paul Weigl, Zhenmin Liang, Kathryn Halifax, W. Edward Lindup and David J. Back
Drug Metabolism and Disposition March 1, 2001, 29 (3) 299-303;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir

John W. Holladay, Michael J. Dewey, Bozena B. Michniak, Hugh Wiltshire, Daniel L. Halberg, Paul Weigl, Zhenmin Liang, Kathryn Halifax, W. Edward Lindup and David J. Back
Drug Metabolism and Disposition March 1, 2001, 29 (3) 299-303;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ontogeny of CPPGL
  • Expression of AKR and SDR Isoforms in the Human Intestine
  • Metabolism of Lufotrelvir in Humans
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics